Successful Completion of Subsequent Offering
(Thomson Reuters ONE) -
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE IN THE PROSPECTUS.
Tromsø, Norway, 11 February 2011 - Biotec Pharmacon ASA (OSE:BIOTEC)
Reference is made to the announcement dated 23 December 2010 and the prospectus
dated 27 January 2011 (the "Prospectus") concerning the subsequent offering of
up to 1,200,000 shares in Biotec Pharmacon ASA at a subscription price of NOK
6.30.
The subsequent offering ended on Thursday 10 February 2011 at 17:30 CET, and was
significantly oversubscribed. As a result, Biotec Pharmacon will issue
1,200,000 new shares at NOK 6.30 per share raising gross proceeds of NOK 7.56
million.
All subscribers being allotted offer shares will receive a letter confirming the
number of offer shares allotted to the subscriber and the corresponding amount
to be paid. This letter will be distributed shortly.
Payment of the shares will fall due on 17 February 2011 and delivery will take
place on or about 22 February 2011. Following registration of the shares the
total number of issued shares will increase by 1,200,000, from 27,137,910 to
28,337,910 shares.
The offering is managed by SEB Enskilda.
This information is subject of the disclosure requirements acc. to §5-12
(Norwegian Securities Trading Act).
For further information, please contact:
Svein W. F. Lien, CEO
Mobile: +47 92 28 93 23
Arvid Vangen, VP Finance & Administration
Phone: +47 77 64 89 12
Mobile: +47 95 03 87 94
About Biotec Pharmacon:
Biotec Pharmacon is a biopharmaceutical company that develops and manufactures
new immunomodulatory products and cold adapted marine enzymes. The company
focuses on new and effective solutions within wound care, cancer therapies and
other immune related disease areas, and aspires to become a leading supplier of
novel enzymes for diagnostics and genetic research.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biotec Pharmacon ASA via Thomson Reuters ONE
[HUG#1488106]
Unternehmensinformation / Kurzprofil:
Datum: 11.02.2011 - 14:21 Uhr
Sprache: Deutsch
News-ID 51387
Anzahl Zeichen: 2884
contact information:
Town:
Tromsø
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 209 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Successful Completion of Subsequent Offering"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotec Pharmacon ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
